Remember those drug trials that are going on regarding COVID-19? One of them concerns the antiviral remdesivir.
First results are in:
New results from a clinical trial conducted by the National Institute of Allergy and Infectious Diseases establish the drug as the standard of care for Covid-19, which has killed 50,000 people in the U.S. so far, said agency Director Anthony Fauci. He likened the good news about remdesivir to the discovery of the first medicine found to help treat HIV more than three decades ago.
That’s a pretty strong endorsement. And because it’s Fauci saying it and not Trump, the MSM might be a bit less likely to go on the attack.
Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.
An independent data and safety monitoring board (DSMB) overseeing the trial met on April 27 to review data and shared their interim analysis with the study team. Based upon their review of the data, they noted that remdesivir was better than placebo from the perspective of the primary endpoint, time to recovery, a metric often used in influenza trials. Recovery in this study was defined as being well enough for hospital discharge or returning to normal activity level.
Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (p=0.059).
Several things seem important here. This was a trial of the drug against placebo, one of the first of that type. The patients who received it were already in dire straits, and so it is particularly impressive in that population. The change in death rate isn’t up to what one might hope (it isn’t up to what I hoped, anyway). But it’s still in the right direction, and it’s highly possible that if the drug were given earlier it would be more effective in that regard.
Remdesivir is not an innocuous drug (in fact, I don’t think there is such a thing). So I don’t think it will necessarily be given to patients with mild symptoms, because of possible side effects involving liver enzyme and GI problems. But ultimately it might be very helpful for those with moderate to serious symptoms, and I believe there will be additional drugs proven to be of value as well.
